Neurology Medical News about malignant gliomas;antiangiogenic strategies

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Antiangiogenic strategies for treatment of malignant gliomas
Neurotherapeutics, 07/01/09

Chi AS et al. - A review of antiangiogenic strategies for treatment of malignant gliomas (MG) summarizes clinical experience with antiangiogenic therapy in MG pts, major issues for use and development of these agents, and strategies based on initial gains seen with antiangiogenic agents.

Methods

Review of antiangiogenic strategies for treatment of MG

Results

Studies are ongoing for numerous antiangiogenic agents with diverse mechanisms of action in treatment of GBM pts
Early clinical trials suggest that antiangiogenic drugs, which target blood vessels of these highly angiogenic tumors, may have clinical benefit in GBM pts
Antiangiogenic agents have potent antiedema and steroid-sparing effects; emerging data suggest modest improvement in progression-free survival
Post-treatment with antiangiogenic agents, a major challenge is interpretation of radiographic changes
Reliable radiographic and biologic markers are lacking to predict which pts benefit from treatment and accurately indicate response and progression during therapy
Most pts treated with antiangiogenic drugs eventually progress

<< Previous
Motor abnormalities in premanifest persons with Huntington's...

Next >>
Operative techniques for gliomas and the value of extent of...